FindTrial
Sign In

TS-172

DRUG6 trials

Sponsors

Taisho Pharmaceutical Co., Ltd.

Conditions

Healthy Adult Male SubjectsHealthy Adult SubjectsHyperphosphatemia Patients on HemodialysisPatients With Mild or Moderate Hepatic ImpairmentPatients on Hemodialysis

Phase 1

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)
CompletedNCT04979572
Taisho Pharmaceutical Co., Ltd.Healthy Adult Subjects
Start: 2021-08-16End: 2022-01-26Updated: 2025-02-28
An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
CompletedNCT06849778
Taisho Pharmaceutical Co., Ltd.Patients on Hemodialysis
Start: 2025-03-22End: 2025-04-24Updated: 2025-05-15
A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects
CompletedNCT07084961
Taisho Pharmaceutical Co., Ltd.Healthy Adult Male Subjects
Start: 2025-08-05End: 2025-09-16Updated: 2025-10-03
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
RecruitingNCT07231029
Taisho Pharmaceutical Co., Ltd.Patients With Mild or Moderate Hepatic Impairment
Start: 2025-12-23End: 2026-10-31Target: 24Updated: 2026-01-09

Phase 2

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
CompletedNCT06745518
Taisho Pharmaceutical Co., Ltd.Hyperphosphatemia Patients on Hemodialysis
Start: 2025-01-06End: 2025-07-22Updated: 2025-08-07

Phase 3

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
RecruitingNCT07285304
Taisho Pharmaceutical Co., Ltd.Hyperphosphatemia Patients on Hemodialysis
Start: 2025-12-01End: 2027-07-31Target: 300Updated: 2025-12-16